Pharmaron Beijing Co., Ltd. provided earnings guidance for the financial year ended December 31, 2022. For the period, the company expects the revenue in the range of CNY 10,123.5268 million to CNY 10,346.8399 million. Growth compared with the same period of last year is 36% - 39%.

Net profit attributable to owners of the parent is expected to be in the range of CNY 1,312.2126 million to CNY 1,445.0949 million. Growth compared with the same period of last year of -21% to ­ -13%. Basic earnings per share is expected to be in the range of CNY 1.1096 to ­1.2220.